Deucravacitinib Impurity NEW

Deucravacitinib Impurity ;1609392-27-9

Product Information

• Product Code：D084000

• English Name：Deucravacitinib

• English Alias：6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide

• CAS No.：1609392-27-9

• Molecular Formula：C₂₀H₁₉D₃N₈O₃

• Molecular Weight：425.46

Advantages

• High-Purity Guarantee：Confirmed by HPLC (≥99.5%), combined with multiple techniques such as NMR (1H, 13C, including deuterium signal analysis), HRMS, and elemental analysis, providing accurate reference standards for drug research, development, and quality control.

• Excellent Stability：Stable for 36 months at -20℃ under light-protected, sealed storage; degradation rate <0.2% in common solvents (such as DMSO, acetonitrile - water system) within 6 months, ensuring reliable experimental data.

Applications

• Drug Development：As a novel tyrosine kinase 2 (TYK2) inhibitor, it is used in the development of drugs for autoimmune diseases such as psoriasis. It regulates the immune response and reduces the release of inflammatory factors by inhibiting the TYK2 signaling pathway.

• Preclinical Research：In pharmacokinetic studies, its deuterated structure is utilized to explore the metabolic pathways and elimination patterns in vivo, optimizing dosing regimens; in pharmacodynamic studies, it assesses the therapeutic effects on disease models.

• Quality Control：Used for UPLC-MS/MS detection of Deucravacitinib in active pharmaceutical ingredients and formulations, controlling impurity content to meet ICH Q3A and Q3B standards, ensuring drug quality and safety.

Background Description

Research Status

• Clinical Application Progress：Approved for the treatment of psoriasis. Data from multiple Phase III clinical trials show that it significantly improves patients' skin symptoms and quality of life compared with placebo; clinical trials for rheumatoid arthritis, systemic lupus erythematosus, and other diseases are ongoing to explore broader indications.

• In-Depth Mechanism Research：The binding mode of Deucravacitinib to the TYK2 protein is analyzed by cryo-electron microscopy to clarify the molecular mechanism of its highly selective inhibition; gene editing techniques are used to knock down or overexpress TYK2 to further verify its regulatory effect on downstream signaling pathways.

• Formulation Optimization：Research on new formulation technologies, such as nanoparticle delivery systems and sustained-release formulations, to improve drug bioavailability and patient compliance; evaluate the release characteristics and stability of different formulations in vitro and in vivo to provide better choices for clinical applications

WhatsAPP: +86 17320513646
E-mail: anna@molcoo.com

NOTE！

We can also customize related analogues and modified peptides including HPLC, MS, 1H-NMR, MS, HPLC, IR, UV, COA, MSDS.
This product is intended for laboratory use only!

WhatsAPP: +86 17320513646
E-mail: anna@molcoo.com

NEW IN STOCK!

The Molcoo Laboratory added drug impurity reference standards, including Baricitinib, Piperazine, Benzylpenicillin, Tranilast and multiple N-Nitroso drug impurities! Now available for immediate delivery!